HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Modern Dental Group (3600.HK) - Insights on Recent Rally of Stock Price and Future Outlook

Pre-IPO Shanghai Conant Optical - Here Are the Strength and the Concerns

Pre-IPO Keymed Biosciences - Challenges Are Inevitable Despite Some Advantages on Pipeline

Presentation for Webinar: 2021 High Conviction-Investment Opportunities in China Healthcare Industry

Hygeia Healthcare Group (6078.HK) - The Investment Logic, the Key Catalyst and the Risk Factors

WuXi Biologics (2269 HK) - The Strength and the Potential Risk

Gravity Works As WeWork Doesn't; Now Plan B

Bifurcated Chinese Express Market Developing

Equity Bottom-Up

<p>The presentation today would mainly include the following parts:</p>
<ul>
<li>2020 and 2021Q1 financial results</li>
<li>Market potential </li>
<li>Business analysis </li>
<li>Financial Analysis (<a href="https://www.smartkarma.com/entities/topchoice-medical-corporation" target="_blank" data-smartkarma-citation="entities:1102:1" rel="noopener">Topchoice Medical (600763 CH)</a> vs <a href="https://www.smartkarma.com/entities/aier-eye-hospital-group-co-ltd" target="_blank" data-smartkarma-citation="entities:1103:1" rel="noopener">Aier Eye Hospital Group (300015 CH)</a>)</li>
<li>Summary</li>
<li>Risk disclosure</li>
</ul>

The presentation today would mainly include the following parts:

2020 and 2021Q1 financial results
Market potential 
Business analysis 
Financial Analysis (Topchoice Medical (600763 CH) vs Aier Eye Hospital Group (300015 CH))
Summary
Risk disclosure


Presentation on Apr.12: 2021 High Conviction Ideas - Topchoice Medical (600763.CH)